Antares Pharma's phase 3 study of Anturol gel to treat overactive bladder meets primary endpoint
Friday, July 30, 2010 18:00 IST Ewing, New Jersey
Antares Pharma, Inc announced positive results from its phase-3 study of Anturol Gel in patients with overactive bladder (OAB). The study met its primary endpoint of a statistically